DUBLIN, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesion, announced that Tran Nguyen, the Company's Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014, at 10:55 AM EST. The conference will be held at the Crowne Plaza Hotel in New York.
A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a reply of the webcast will be available on the Company's website for 90 days.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and its antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the Company's web site at www.prothena.com.
CONTACT: Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com
Media: Angela Bitting
925-202-6211, angela.bitting@prothena.com
